Triplication alpha-synuclein iPSCs (MRC Centre for Regenerative Medicine)

https://neurodegenerationresearch.eu/survey/triplication-alpha-synuclein-ipscs-mrc-centre-for-regenerative-medicine/

Name of Resource

Triplication alpha-synuclein iPSCs (MRC Centre for Regenerative Medicine)

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Tilo

Name of Principal Investigator - Last name

Kunath

Address of institution -Institution

MRC Centre for Regenerative Medicine, Univerisity of Edinburgh

Address of institution - Street address

5 Little France Drive

Address of institution - City

Edinburgh

Address of institution - Postcode

EH16 4UU

Country

United Kingdom

Website

http://www.crm.ed.ac.uk/people/tilo-kunath

Contact email

tilo.kunath@ed.ac.uk

Summary

Human induced pluripotent stem cells (iPSCs) were established from a family with triplication of the alpha-synuclein gene. A collection of lines were derived from a female Parkinson's patient, AST, and also from her unaffected daughter, NAS. These lines were published in Devine et al, 2011 (PMID:21863007). A gene editted isogenic control line, AST23-2KO6, was created from a PD line, AST23. All the iPSC lines have been deposited into EBiSC (https://www.ebisc.org/) and are available for academic and industrial projects.

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions? (1)

Parkinson's disease & PD-related disorders

Q1b. Does your resource hold

Induced Pluripotent Stem Cells (iPSC)

Q2a. Does the resource act as a centre for access and distribution to external groups (who are not the Principal Investigators (PI) for the resource)?

Yes

Q2b. If Yes, what procedures and rules apply for access?

Access independent of collaboration with PI| International access| Access to industry

Q3a. Does your resource develop experimental models (animal/cell) for external groups?

Yes

Q3b. If YES and your resource is related to an ANIMAL model, what types of models are provided?
Q3c. If YES and your resource is related to a CELL model, what types of models are provided?

Patient derived| Gene edited

Q4a. Is this activity supported as:

A collaboration

Q4b. Do you deposit what you supply in any kind of central repository?

Yes

Disease
Species
Available to external user
Full phenotypic character
Please indicate the phenotypes

List of genotypes or other subtypes
Q5b. Cognitive function, No of models
Q5b. Cognitive function, Available to external users
Q5b. Cognitive function, Full phenotypic characterisation
Q5b. Cognitive function, Nature of phenotype
Q5b. Motor function, No of models
Q5b. Motor function, Available to external users
Q5b. Motor function, Full phenotypic characterisation
Q5b. Motor function, Nature of phenotype
Q5b. Physiological function, no of models
Q5b. Physiological function, Available to external users
Q5b. Physiological function, Full phenotypic characterisation
Q5b. Physiological function, Nature of phenotype
Q5b. Other function (please specify), no of models
Please specify other function
Q5b. Other function (please specify), Available to external users
Q5b. Other function (please specify), Full phenotypic characterisation
Q5b. Other function (please specify), Nature of phenotype
Q6. Please indicate if your resource is already linked into European or international consortia or networks?

EBiSC, European Bank of induced Stem Cells

Q7a. Is maintenance of this resource dependent on continued funding?

Yes

Q7b. If yes, when does the current funding period end?
Q7c. What is the expected lifespan of the resource (in years)?

Indefinite

Q7d. Are there other plans affecting future use that it may be useful to know?

No

Types:
Experimental Models

Member States:
United Kingdom

Diseases:
N/A

Years:
2016

Database Categories:
N/A

Database Tags:
N/A